It is to be noted that while most human cells express detectable levels of HER2, we demonstrate here that HER2-overexpressing cancer cells are more sensitive to lower and clinically relevant concentrations of T-DM1, promoting sensitization to oncolytic VSVΔ51. This evidence concerns the gene ERBB2 and cancer.